Barclays
SFE

Barclays’s Safeguard Scientifics, Inc. SFE Stock Holding History

Barclays’s Portfolio SFE Stock Details SFE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		– Sell
-1,000
Closed -$11K – 7376
2019
Q1 		$11K Hold
1,000
– – ﹤0.01% 6535
2018
Q4 		$9K Buy
+1,000
New +$8.72K ﹤0.01% 6230

Other funds holding SFE

YCM
Yakira Capital Management Westport, Connecticut $342M AUM 26.97% 1-Year Est. Return
First Manhattan
First Manhattan New York $36.1B AUM 11.5% 1-Year Est. Return
NRC
North Run Capital Boston, Massachusetts $43.5M AUM 38.24% 1-Year Est. Return
CCM
Contrarian Capital Management Greenwich, Connecticut $357M AUM 18.27% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CM
CM Management Gulf Breeze, Florida $120M AUM 37.12% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
MAP
Madison Avenue Partners New York $2.3B AUM 115.82% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
CP
Clayton Partners Berkeley, California $138M AUM 38.58% 1-Year Est. Return

Barclays's SFE Position: Q4 2021 in Review

Barclays sold out of Safeguard Scientifics, Inc. (SFE) in Q4 2021, closing a stake of 2,841 shares — an estimated $25K sold.

Barclays first reported a position in SFE in Q2 2013 and held it in 32 quarters. The position peaked at $257K in Q1 2019. 63 funds tracked by Wall St. Rank hold SFE as of Q4 2021.

  • Barclays reported no remaining Safeguard Scientifics, Inc. position as of Q4 2021 after selling out during the quarter.
  • Barclays sold 2,841 Safeguard Scientifics, Inc. shares in Q4 2021, an estimated $25K.
  • Barclays first reported a position in Safeguard Scientifics, Inc. in Q2 2013 and held it in 32 quarters.
  • Barclays's Safeguard Scientifics, Inc. position peaked at $257K in Q1 2019.
  • 63 funds tracked by Wall St. Rank held Safeguard Scientifics, Inc. as of Q4 2021.

Based on Barclays's 13F filing for Q4 2021, filed 14 Feb 2022.